News

The technology provides a platform of diagnostic tests used by physicians and researchers to monitor the success of anti-HIV treatment by determining drug resistance and disease strength of

The company has said that it has begun accepting orders for the solution and has started commercial production of the solution’s components for shipment during the first quarter

Net income of $2.0 million for the fourth quarter of 2008 and $3.1 million of net income for 2008 Consolidated fourth quarter revenue of $28.2 million, up 31

The Realism study is a prospective, multi-center, continued access registry of the Everest II study. The Realism study consists of two arms: a high risk arm and a

In a study conducted by Barry Eppley, 23 female patients (ages 19 to 37) with problematic menstrual issues used the Allay patch continuously for five days when the

Arlington Neonatal Intensive Care is a two-physician practice that staffs the Level III neonatal intensive care unit (NICU) at Texas Health Arlington Memorial Hospital, which has annual patient

In addition, Terrance Gregg, DexCom’s president and CEO, also purchased 150,000 additional shares of common stock in this offering at a per share price of $3.12, which represents

The Phase III Atlas study was stopped early on the recommendation of an independent data safety monitoring board after a pre-planned interim analysis showed that combining Tarceva and

Net loss was $5.9 million, or $(0.10) per share, which against revenue of $40.4 million and a net loss of $5.3 million, or $(0.10) per share, in the